Spelling suggestions: "subject:"bucker."" "subject:"cucker.""
41 |
Öko-Effizienz im Zuckerrübenanbau - Ansatz zur Beschreibung einer nachhaltigen Entwicklung /Fuchs, Julia. January 2009 (has links)
Zugl.: Göttingen, Universiẗat, Diss., 2009.
|
42 |
Renal Mass Reduction Increases the Response to Exogenous Insulin Independent of Acid-Base Status or Plasma Insulin Levels in RatsMannon, Elinor C., Sartain, Christina L., Wilkes, Trevin C., Sun, Jingping, Polichnowski, Aaron J., O'Connor, Paul M. 01 September 2021 (has links)
Impairments in insulin sensitivity can occur in patients with chronic kidney disease (CKD). Correction of metabolic acidosis has been associated with improved insulin sensitivity in CKD, suggesting that metabolic acidosis may directly promote insulin resistance. Despite this, the effect of acid or alkali loading on insulin sensitivity in a rodent model of CKD (remnant kidney) has not been directly investigated. Such studies could better define the relationship between blood pH and insulin sensitivity. We hypothesized that in remnant kidney rats, acid or alkali loading would promote loss of pH homeostasis and consequently decrease insulin sensitivity. To test this hypothesis, we determined the impact of alkali (2 wk) or acid (5-7 days) loading on plasma electrolytes, acid-base balance, and insulin sensitivity in either sham control rats, 2/3 nephrectomized rats, or 5/6 nephrectomized rats. Rats with 5/6 nephrectomy had the greatest response to insulin followed by rats with 2/3 nephrectomy and sham control rats. We found that treatment with 0.1 M sodium bicarbonate solution in drinking water had no effect on insulin sensitivity. Acid loading with 0.1 M ammonium chloride resulted in significant reductions in pH and plasma bicarbonate. However, acidosis did not significantly impair insulin sensitivity. Similar effects were observed in Zucker obese rats with 5/6 nephrectomy. The effect of renal mass reduction on insulin sensitivity could not be explained by reduced insulin clearance or increased plasma insulin levels. We found that renal mass reduction alone increases sensitivity to exogenous insulin in rats and that this is not acutely reversed by the development of acidosis.
|
43 |
Obesity and Age-Related Changes in the Brain of the Zucker Lepr fa/fa RatsTomassoni, Daniele, Martinelli, Ilenia, Moruzzi, Michele, Di Bonaventura, Maria Vittoria Micioni, Cifani, Carlo, Amenta, Francesco, Tayebati, Seyed Khosrow 20 April 2023 (has links)
Metabolic syndrome (MetS) is an association between obesity, dyslipidemia, hyperglycemia, hypertension, and insulin resistance. A relationship between MetS and vascular dementia was hypothesized. The purpose of this work is to investigate brain microanatomy alterations in obese Zucker rats (OZRs), as a model of MetS, compared to their counterparts lean Zucker rats (LZRs). 12-, 16-, and 20-weeks-old male OZRs and LZRs were studied. General physiological parameters and blood values were measured. Immunochemical and immunohistochemical techniques were applied to analyze the brain alterations. The morphology of nerve cells and axons, astrocytes and microglia were investigated. The blood–brain barrier (BBB) changes occurring in OZRs were assessed as well using aquaporin-4 (AQP4) and glucose transporter protein-1 (GLUT1) as markers. Body weight gain, hypertension, hyperglycemia, and hyperlipidemia were found in OZRs compared to LZRs. In the frontal cortex and hippocampus, a decrease of neurons was noticeable in the older obese rats in comparison to their age-matched lean counterparts. In OZRs, a reduction of neurofilament immunoreaction and gliosis was observed. The BBB of older OZRs revealed an increased expression of AQP4 likely related to the development of edema. A down-regulation of GLUT1 was found in OZRs of 12 weeks of age, whereas it increased in older OZRs. The behavioral analysis revealed cognitive alterations in 20-week-old OZRs. Based on these results, the OZRs may be useful for understanding the mechanisms through which obesity and related metabolic alterations induce neurodegeneration.
|
44 |
Cardiovascular Changes Related to Metabolic Syndrome: Evidence in Obese Zucker RatsMartinelli, Ilenia, Tomassoni, Daniele, Moruzzi, Michele, Roy, Proshanta, Cifani, Carlo, Amenta, Francesco, Tayebati, Seyed Khosrow 11 January 2024 (has links)
Metabolic syndrome (MetS) is a predictor of cardiovascular diseases, commonly
associated with oxidative stress and inflammation. However, the pathogenic mechanisms
are not yet fully elucidated. The aim of the study is to evaluate the oxidative status and
inflammation in the heart of obese Zucker rats (OZRs) and lean Zucker rats (LZRs) at different
ages. Morphological and morphometric analyses were performed in the heart. To study the
oxidative status, the malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), protein oxidation,
and antioxidant enzymes were measured in plasma and heart. To elucidate the inflammatory
markers involved, immunohistochemistry and Western blot were performed for cellular adhesion
molecules and proinflammatory cytokines. OZRs were characterized by hypertension, hyperlipidemia,
hyperglycemia, and insulin resistance. The obesity increased MDA and decreased the activities
of superoxide dismutase (SOD) in plasma as well as in the heart, associated with cardiomyocytes
hypertrophy. OxyBlot in plasma and in heart showed an increase of oxidativestate proteins in OZRs.
Vascular cell adhesion molecule-1, interleukin-6, and tumor necrosis factor-α expressions in OZRs
were higher than those of LZRs. However, these processes did not induce apoptosis or necrosis of
cardiomyocytes. Thus, MetS induces the lipid peroxidation and decreased antioxidant defense that
leads to heart tissue changes and coronary inflammation
|
45 |
Efeitos da privação de sono sobre parâmetros cardiovasculares em ratos machos e fêmeas / Effects of sleep deprivation in cardiovascular parameters in male and female ratsTenório, Neuli Maria [UNIFESP] 29 June 2011 (has links) (PDF)
Made available in DSpace on 2015-07-22T20:49:58Z (GMT). No. of bitstreams: 0
Previous issue date: 2011-06-29 / A redução no tempo de sono caracteriza a sociedade moderna. A associação recíproca entre a duração do sono e o ganho de peso tem sido atualmente explorada. Contudo, as conseqüências desses fatores no sistema cardiovascular permanecem não completamente elucidadas, principalmente quando verificadas ao longo da vida. Além disso, as conseqüências da privação de sono ainda podem sofrer a influência do fator sexo. Assim, o objetivo do presente estudo foi verificar o impacto da privação de sono aguda associada à obesidade em ratas Zucker de diferentes idades (Artigo 1) e comparar os efeitos da privação de sono paradoxal (PSP) e restrição de sono (RS) crônica em ratos eutróficos machos e fêmeas (Artigo 2) nos parâmetros cardiovasculares (Artigos 1 e 2) e hormonal (Artigo 2). Para a realização do Artigo 1, ratas Zucker fêmeas magras e obesas de 3, 6 e 15 meses de idade foram distribuídas em grupos controle (CTRL, gaiolas-moradia) ou privação de sono (PS). Para o Artigo 2, ratos adultos machos e fêmeas da linhagem Wistar foram distribuídos nos grupos: controle (CTRL, gaiolas-moradia), PSP (ratos submetidos a PSP por 96 horas) ou RS (ratos submetidos à RS por 21 dias). Para ambos os artigos, os animais foram anestesiados após respectivo protocolo de PS ou tempo equivalente nos grupos CTRL, para cateterização da artéria e veia femorais. Em seguida, o índice de sensibilidade baroreflexa foi mensurado por infusões de fenilefrina (resposta bradicárdica) e nitroprussiato de sódio (resposta taquicárdica). No caso do Artigo 2, outro grupo de animais foi utilizado para a coleta sanguínea a fim de avaliar as concentrações de hormônio adrenocorticotrófico (ACTH). No Artigo 1, observamos que a obesidade resultou em disfunção da resposta taquicárdica nos animais desde os 3 meses de idade. Aos 6 e 15 meses de idade, a resposta bradicárdica e taquicárdica foram significativamente menores em animais obesos comparados aos respectivos grupos magros. Aos 15 meses de idade, a interação entre obesidade, PS e idade provocou as maiores conseqüências no sistema cardiovascular, uma vez que aumentou a pressão arterial, a freqüência cardíaca e reduziu a sensibilidade baroreflexa. No Artigo 2, os resultados mostraram que a pressão arterial média foi significativamente maior no grupo RS comparada ao grupo CTRL em ambos os sexos. Em fêmeas, a freqüência cardíaca foi significativamente maior após a PSP comparada ao respectivo grupo CTRL. O protocolo de RS atenuou a resposta baroreflexa vagal similarmente em ratos machos e fêmeas. A resposta baroreflexa simpática foi atenuada nos grupos PSP e RS, contudo, em fêmeas este parâmetro foi afetado apenas após o procedimento de PSP. Nenhuma diferença significativa em relação ao sexo foi observada para qualquer parâmetro cardiovascular em ratos da linhagem Wistar, apenas a PSP aumentou significativamente as concentrações de ACTH comparado ao grupo CTRL em ambos os sexos. Em conjunto, esses resultados sugerem que diferentes durações de perda de sono levam a conseqüências específicas nos parâmetros cardiovasculares e hormonais e estes efeitos foram similares entre ratos machos e fêmeas no caso de ratos eutróficos. Em animais obesos, a associação entre os fatores de risco (obesidade, PS e idade) exerceram as piores consequências nos parâmetros cardiovasculares analisados. / Curtailment of sleep time is a characteristic of modern society, and the reciprocal association between duration of sleep and weight gain has been under scrutiny as of late. The consequences of such factors upon the cardiovascular system remain to be fully elucidated, particularly along a full life span. Moreover, the consequences of sleep deprivation may also be influenced by the gender. The current study thus purported to examine the impact of acute sleep deprivation associated to obesity in female Zucker rats of different ages (Paper 1) and to compare the effects of paradoxical sleep deprivation (PSD) and chronic sleep restriction (SR) in male and female eutrophic rats (Paper 2) upon the cardiovascular (Papers 1 and 2) and hormonal (Paper 2 ) parameters. For the experiments described in Paper 1 lean and obese female Zucker rats 3, 6, and 15 months old were distributed into either control groups (CTRL, homecage) or sleep deprived (SD). For the experiments of Paper 2 adult female and male Wistar rats were distributed in either control groups (CTRL, home-cage) or in Paradoxical Sleep Deprivation for 96h groups (PSD-96h) or Sleep Restriction for 21 days groups (SR 21 days). In both experiments the subjects were anesthetized according to respective SD protocol or equivalent time in the CTRL groups, after which a catheter was placed in their femoral artery and vein. The baroreflex sensibility index was measured by means of phenilephrine (bradicardiac response) and sodium nitroprussiate (taquicardiac response). For the experiments conducted for Paper 2 a different group of subjects was used for blood harvesting to assess the concentrations of adrenocorticotrophic hormone (ACTH). In Paper 1 we observed that obesity resulted in dysfunctional taquicardia in subjects from 3 months of age and on. At 6 and 15 months of age the bradicardiac and taquicardiac response were significantly smaller in obese subjects when compared to respective lean groups. At 15 months of age the interaction between obesity, SD and age caused the greatest consequences in the cardiovascular system as arterial. Results of Paper 2 show that the average arterial pressure was significantly higher in the SR group when compared to the CTRL group in both genders. In females, cardiac frequency was significantly higher after PSD when compared to respective controls. The SR protocol attenuated the vagal baroreflex response similarly in males and females. The sympathetic baroreflex response was attenuated in the PSD and SR groups, but in females this parameter was affected only after PSD. No significant difference in relation to gender was observed in any of the cardiovascular parameters. PSD did increase ACTH concentrations significantly when compared to controls of both genders. The body of results yielded by both studies suggests that different periods of lost sleep lead to specific consequences in cardiovascular and hormonal parameters, and such effects were similar in male and female rat subjects. / TEDE
|
46 |
Impact de l’insuffisance rénale chronique sur les transporteurs de glucose et les effets subséquents sur la résistance à l’insulineDumayne, Christopher 12 1900 (has links)
Parmi l’ensemble des désordres métaboliques retrouvés en insuffisance rénale chronique (IRC), la résistance à l’insuline demeure l’un des plus importantes à considérer en raison des risques de morbidité et de mortalité qu’elle engendre via les complications cardiovasculaires. Peu d’études ont considéré la modulation de transporteurs de glucose comme mécanisme sous-jacent à l’apparition et à la progression de la résistance à l’insuline en IRC. Nous avons exploré cette hypothèse en étudiant l’expression de transporteurs de glucose issus d’organes impliqués dans son homéostasie (muscles, tissus adipeux, foie et reins) via l’utilisation d’un modèle animal d’IRC (néphrectomie 5/6e). La sensibilité à l’insuline a été déterminée par un test de tolérance au glucose (GTT), où les résultats reflètent une intolérance au glucose et une hyperinsulinémie, et par les études de transport au niveau musculaire qui témoignent d’une diminution du métabolisme du glucose en IRC (~31%; p<0,05). La diminution significative du GLUT4 dans les tissus périphériques (~40%; p<0,001) peut être à l’origine de la résistance à l’insuline en IRC. De plus, l’augmentation de l’expression protéique de la majorité des transporteurs de glucose (SGLT1, SGLT2, GLUT1; p<0,05) au niveau rénal en IRC engendre une plus grande réabsorption de glucose dont l’hyperglycémie subséquente favorise une diminution du GLUT4 exacerbant ainsi la résistance à l’insuline. L’élévation des niveaux protéiques de GLUT1 et GLUT2 au niveau hépatique témoigne d’un défaut homéostatique du glucose en IRC. Les résultats jusqu’ici démontrent que la modulation de l’expression des transporteurs de glucose peut être à l’origine de la résistance à l’insuline en IRC.
L’impact de la parathyroïdectomie (PTX) sur l’expression du GLUT4 a été étudié étant donné que la PTX pourrait corriger l’intolérance au glucose en IRC. Nos résultats démontrent une amélioration de l’intolérance au glucose pouvant être attribuable à la moins grande réduction de l’expression protéique du GLUT4 dans les tissus périphériques et ce malgré la présence d’IRC. L’excès de PTH, secondaire à l’hyperparathyroïdie, pourrait alors être à l’origine de la résistance à l’insuline en IRC en affectant l’expression du GLUT4.
L’IRC partage de nombreuses similitudes avec le prédiabète quant aux défaillances du métabolisme du glucose tout comme l’hyperinsulinémie et l’intolérance au glucose. Aucune étude n’a tenté d’évaluer si l’IRC pouvait ultimement mener au diabète. Nos résultats ont par ailleurs démontré que l’induction d’une IRC sur un modèle animal prédisposé (rats Zucker) engendrait une accentuation de leur intolérance au glucose tel que constaté par les plus hautes glycémies atteintes lors du GTT. De plus, certains d’entre eux avaient des glycémies à jeun dont les valeurs surpassent les 25 mmol/L. Il est alors possible que l’IRC puisse mener au diabète via l’évolution de la résistance à l’insuline par l’aggravation de l’intolérance au glucose. / Of all metabolic disorders found in chronic renal failure (CRF), insulin resistance remains one of the most important to consider because of the risk of morbidity and mortality it causes via cardiovascular complications. Few studies have considered the modulation of glucose transporters as the mechanism underlying the emergence and progression of insulin resistance in CRF. We explored this hypothesis by studying the expression of glucose transporters from organs involved in its homeostasis (muscle , fat , liver and kidneys) through the use of an animal model reflecting CRF (5/6th nephrectomy). The insulin sensitivity was determined by a glucose tolerance test (GTT), where the results reflect glucose intolerance and hyperinsulinemia , and transport studies in muscle show a decrease in glucose uptake in CRF ratss (~31% , p<0.05). The significant decrease in GLUT4 in peripheral tissues (~40%, p<0.001) may be the cause of insulin resistance in CRF. Furthermore, increased protein expression of the majority of glucose transporters (SGLT1, SGLT2, GLUT1, p<0.05) within the kidney in CRF causes greater glucose reabsorption in which consequential hyperglycemia promotes a decrease in GLUT4 thus exacerbating insulin resistance. Elevated protein levels of GLUT1 and GLUT2 in the liver reflects an impaired glucose homeostasis in CRF. The results show that the modulation of the expression of glucose transporters may be responsible for insulin resistance in CRF.
The impact of parathyroidectomy (PTX) on the expression of GLUT4 was studied since PTX is known to correct glucose intolerance in CRF. Our results show an improvement in glucose intolerance which may be due to less reduction of GLUT4 protein expression in peripheral tissues despite the presence of CRF. The excess of PTH, linked to secondary hyperparathyroidism, could be held responsible to the presence of insulin resistance in CRF by affectant GLUT4 expression.
CRF shares many similarities with prediabetes in regards to impaired glucose metabolism such as hyperinsulinemia and glucose intolerance. No studies have attempted to assess whether CRF could lead to diabetes. Our results demonstrated that the induction of CRF in a predisposed animal model (Zucker rats) provoked greater glucose intolerance as evidenced by the highest blood glucose levels reached in the GTT. In addition, some of them had fasting blood glucose levels whose values exceeded 25 mmol/L. It is therefore possible that CRF can lead to diabetes through the evolution of insulin resistance by the worsening of glucose intolerance.
|
47 |
Lipogénèse de la paroi artérielle : régulation de son expression et anomalies dans l'insulino-résistance et le diabète / Lipogenesis in arterial wall : regulation of its expression and abnormalities in insulin-resistance and diabetesHamlat, Nadjiba 06 June 2010 (has links)
Nous avons étudié l’expression et la régulation de la lipogenèse dans les aortes et CMLV et déterminé si elle est modifiée par l’insulino-résistance et le diabète. Les rats Zucker obèses (ZO), diabétiques et Psammomys obesus accumulent plus de lipides dans leurs aortes que leurs contrôles. Cependant l’expression des gènes de la lipogenèse et ceux impliqués dans la captation des acides gras, n’est pas augmentée. Un résultat similaire a été retrouvé dans des pièces d’endartériectomies chez l’homme. Le milieu adipogénique, le glucose ou l’insuline seule stimulent modérément la lipogenèse uniquement dans les CML de Zucker contrôles, aucun effet n’a été observé dans les CML de ZO. Nous avons montré que les effets du TO901317 sur la lipogenèse dans les CMLV sont dus uniquement à l’activation du récepteur nucléaire LXRα, PXR n’a aucun effet. En conclusion, la lipogenèse n’est pas augmentée dans la paroi artérielle durant l’insulino-résistance et le diabète. / We investigated the expression and regulation of lipogenesis in aortas and VSMC and determined if it is modified during metabolic abnormalities. Zucker obese (ZO), diabetic (ZDF) rats, and the high fat diet fed Psammomys obesus accumulated more triglycerides in their aortas than control rats. However the expression of lipogenic genes, or of genes involved in fatty acids uptake, was not increased. Lipogenesis was not increased in human carotid endarterectomy of diabetic compared to non-diabetic patients. The adipogenic medium (ADM), glucose or insulin stimulated moderately lipogenesis but only in VSMC from control rats. No effect was observed in VSMC from ZO. We showed that the lipogenic effects of TO901317observed in VSMC from Zucker control rats are due solely to the nuclear receptor LXRα, PXR agonist had no effect. Conclusion: Lipogenesis is not increased in arterial wall during insulin-resistance and diabetes.
|
48 |
Protein and mRNA Studies of Rat FA1/Pref-1/dlkPersdotter Hedlund, Gabriella January 2007 (has links)
<p>The timing of cell differentiation is important for development and renewal of well functioning organs and tissues. One protein involved in this process is Preadipocyte factor 1 (Pref-1). Most likely, the role of this protein is to maintain cells in an undifferentiated state. </p><p>The work presented in this thesis, has employed the rat as an animal model for the studies of Pref-1. Rat models of obesity (Zucker, ZO) and type II diabetes (Goto-Kakizaki, GK) were used to determine metabolic influence on Pref-1 and adipokine mRNA expression in adipose tissues.</p><p>The Pref-1 cleavage product was purified from rat amniotic fluid and physicochemically characterised. Concentration of Pref-1 in serum, amniotic fluid and urine was determined by ELISA. Soluble Pref-1 and the compartmentalisation of the protein were highly similar to what had previously been demonstrated in mice and humans.</p><p>Immunohistochemistry studies displayed similar staining patterns of Pref-1 in adrenal glands, ovaries and pituitary glands of non-pregnant and pregnant rats. This suggests that pregnancy do not influence the protein expression of Pref-1 in these organs.</p><p>In the GK rats, Pref-1 mRNA was altered and a decrease in the visceral compared to subcutaneous adipose depots was demonstrated, in contrast to the ZO rats. Additionally, adiponectin, leptin, IL-6 and TNF-α mRNA levels were altered in the diabetic strain, indicating that this animal model expresses many of the typical features of type II diabetes.</p><p>In conclusion, the rat is an appropriate model for studies of FA1/Pref-1/dlk. Pref-1 is highly elevated in fetal and maternal serum during pregnancy. However, the expression of Pref-1 in some endocrine tissues did not alter due to pregnancy. The mRNA expression of Pref-1 was altered between adipose depots and demonstrated to be affected by metabolic disturbances in the animals.</p>
|
49 |
Impact de l’insuffisance rénale chronique sur les transporteurs de glucose et les effets subséquents sur la résistance à l’insulineDumayne, Christopher 12 1900 (has links)
Parmi l’ensemble des désordres métaboliques retrouvés en insuffisance rénale chronique (IRC), la résistance à l’insuline demeure l’un des plus importantes à considérer en raison des risques de morbidité et de mortalité qu’elle engendre via les complications cardiovasculaires. Peu d’études ont considéré la modulation de transporteurs de glucose comme mécanisme sous-jacent à l’apparition et à la progression de la résistance à l’insuline en IRC. Nous avons exploré cette hypothèse en étudiant l’expression de transporteurs de glucose issus d’organes impliqués dans son homéostasie (muscles, tissus adipeux, foie et reins) via l’utilisation d’un modèle animal d’IRC (néphrectomie 5/6e). La sensibilité à l’insuline a été déterminée par un test de tolérance au glucose (GTT), où les résultats reflètent une intolérance au glucose et une hyperinsulinémie, et par les études de transport au niveau musculaire qui témoignent d’une diminution du métabolisme du glucose en IRC (~31%; p<0,05). La diminution significative du GLUT4 dans les tissus périphériques (~40%; p<0,001) peut être à l’origine de la résistance à l’insuline en IRC. De plus, l’augmentation de l’expression protéique de la majorité des transporteurs de glucose (SGLT1, SGLT2, GLUT1; p<0,05) au niveau rénal en IRC engendre une plus grande réabsorption de glucose dont l’hyperglycémie subséquente favorise une diminution du GLUT4 exacerbant ainsi la résistance à l’insuline. L’élévation des niveaux protéiques de GLUT1 et GLUT2 au niveau hépatique témoigne d’un défaut homéostatique du glucose en IRC. Les résultats jusqu’ici démontrent que la modulation de l’expression des transporteurs de glucose peut être à l’origine de la résistance à l’insuline en IRC.
L’impact de la parathyroïdectomie (PTX) sur l’expression du GLUT4 a été étudié étant donné que la PTX pourrait corriger l’intolérance au glucose en IRC. Nos résultats démontrent une amélioration de l’intolérance au glucose pouvant être attribuable à la moins grande réduction de l’expression protéique du GLUT4 dans les tissus périphériques et ce malgré la présence d’IRC. L’excès de PTH, secondaire à l’hyperparathyroïdie, pourrait alors être à l’origine de la résistance à l’insuline en IRC en affectant l’expression du GLUT4.
L’IRC partage de nombreuses similitudes avec le prédiabète quant aux défaillances du métabolisme du glucose tout comme l’hyperinsulinémie et l’intolérance au glucose. Aucune étude n’a tenté d’évaluer si l’IRC pouvait ultimement mener au diabète. Nos résultats ont par ailleurs démontré que l’induction d’une IRC sur un modèle animal prédisposé (rats Zucker) engendrait une accentuation de leur intolérance au glucose tel que constaté par les plus hautes glycémies atteintes lors du GTT. De plus, certains d’entre eux avaient des glycémies à jeun dont les valeurs surpassent les 25 mmol/L. Il est alors possible que l’IRC puisse mener au diabète via l’évolution de la résistance à l’insuline par l’aggravation de l’intolérance au glucose. / Of all metabolic disorders found in chronic renal failure (CRF), insulin resistance remains one of the most important to consider because of the risk of morbidity and mortality it causes via cardiovascular complications. Few studies have considered the modulation of glucose transporters as the mechanism underlying the emergence and progression of insulin resistance in CRF. We explored this hypothesis by studying the expression of glucose transporters from organs involved in its homeostasis (muscle , fat , liver and kidneys) through the use of an animal model reflecting CRF (5/6th nephrectomy). The insulin sensitivity was determined by a glucose tolerance test (GTT), where the results reflect glucose intolerance and hyperinsulinemia , and transport studies in muscle show a decrease in glucose uptake in CRF ratss (~31% , p<0.05). The significant decrease in GLUT4 in peripheral tissues (~40%, p<0.001) may be the cause of insulin resistance in CRF. Furthermore, increased protein expression of the majority of glucose transporters (SGLT1, SGLT2, GLUT1, p<0.05) within the kidney in CRF causes greater glucose reabsorption in which consequential hyperglycemia promotes a decrease in GLUT4 thus exacerbating insulin resistance. Elevated protein levels of GLUT1 and GLUT2 in the liver reflects an impaired glucose homeostasis in CRF. The results show that the modulation of the expression of glucose transporters may be responsible for insulin resistance in CRF.
The impact of parathyroidectomy (PTX) on the expression of GLUT4 was studied since PTX is known to correct glucose intolerance in CRF. Our results show an improvement in glucose intolerance which may be due to less reduction of GLUT4 protein expression in peripheral tissues despite the presence of CRF. The excess of PTH, linked to secondary hyperparathyroidism, could be held responsible to the presence of insulin resistance in CRF by affectant GLUT4 expression.
CRF shares many similarities with prediabetes in regards to impaired glucose metabolism such as hyperinsulinemia and glucose intolerance. No studies have attempted to assess whether CRF could lead to diabetes. Our results demonstrated that the induction of CRF in a predisposed animal model (Zucker rats) provoked greater glucose intolerance as evidenced by the highest blood glucose levels reached in the GTT. In addition, some of them had fasting blood glucose levels whose values exceeded 25 mmol/L. It is therefore possible that CRF can lead to diabetes through the evolution of insulin resistance by the worsening of glucose intolerance.
|
50 |
Painful diabetic neuropathy: preclinical studies to improve therapeutic insight.Kathleen Otto Unknown Date (has links)
My PhD research studies, described in this thesis, were designed to document the temporal development of mechanical allodynia, a hallmark symptom of painful diabetic neuropathy (PDN), as well as opioid hyposensitivity using two different rat models of diabetes mellitus (DM). Specifically, the studies were conducted using the streptozotocin (STZ)-diabetic rat model of chemically-induced Type 1 diabetes in two different rat strains, as well as the Zucker Diabetic Fatty (ZDF) rat genetic model of Type 2 diabetes. Additionally, a longitudinal investigation of the effect of basal insulin replacement therapy to restore euglycaemia from 7-days post-STZ administration, on the development of mechanical allodynia in the hindpaws of the STZ-diabetic Wistar rat model of PDN, was conducted. The studies herein also included a longitudinal study to document the temporal development of mechanical allodynia and opioid hyposensitivity in the ZDF rat, which also examined the influence of dietary composition on the time course for the development of mechanical allodynia in the hindpaws, together with opioid hyposensitivity in these animals. In the final section of this thesis, the experiments were designed to examine possible mechanisms that may contribute to the development of opioid hyposensitivity in ZDF diabetic rats. These experiments involved the quantification of opioid receptor messenger ribonucleic acid (mRNA) gene expression as well as μ-opioid receptor (MOP-r) functional responses in tissues collected from 29-wk old diabetic ZDF rats relative to 7-wk old pre-diabetic control ZDF animals. In Chapter One, diabetes mellitus and more specifically its longterm complication, PDN, the focus of this doctoral research program, has been reviewed. Specifically, possible pathogenic mechanisms underlying mechanical allodynia, the relevant diabetic rodent models of PDN, use of insulin replacement therapy in diabetic rodents and its impact on hallmark symptoms of PDN, role of opioid pharmacology, the comparative efficacy of opioids in the treatment of PDN, and possible mechanisms that may underpin the development of opioid hyposensitivity in PDN, including the impact of altered excitatory neurotransmitters, have been reviewed. In Chapter Two, a preliminary study was conducted to investigate the efficacy of 4-wks treatment with Linplants (subcutaneous (s.c.) sustained-release bovine insulin implants) alone and in combination with ActRapid® (s.c. human insulin; 0.05 U to 3.5 U/100 g/day) with respect to glycaemic control in STZ-diabetic Wistar rats, and on acute diabetes characteristics for a 5-wk post-STZ administration period. Briefly, STZ-diabetic rats were divided into three groups: (1) rats which received no insulin treatment, (2) rats which were implanted with one s.c. Linplant at Day 7 post-STZ administration, and (3) rats which received one s.c. Linplant plus a once-daily injection of ActRapid® once diabetes was confirmed at 7-days post-STZ administration. The findings were that following implantation of a single Linplant at Day 7 post-STZ administration, euglycaemia was achieved in 50% of STZ-diabetic rats, with glycaemic control maintained for up to 4-wks post-implantation. Furthermore, once-daily injection of ActRapid™ to animals whose blood glucose levels (BGLs) were not well-controlled through use of Linplants alone, failed to achieve euglycaemia. It is possible that the ActRapid™ doses administered were not sufficient to achieve euglycaemia, and that increasing the doses may provide more effective glycaemic control. However, doubling the mean ActRapid™ dose from 1.63 (+ 0.3) U administered at Day 28 to 2.56 (+ 0.6) U administered at Day 34 post-STZ administration effectively only reduced BGLs by 1.3 mM to 11.6 + 1.6 mM. This suggests that although administering additional large doses of ActRapid™ to STZ-diabetic rats may eventually achieve euglycaemia, this method would presumably not be a more efficient method in achieving euglycaemia compared with the use of dosage-adjustable s.c. Linplants. Group (1) STZ-diabetic rats which were not treated with insulin developed diabetic signs including polydipsia, hyperphagia, decreased rate of body weight gain, and mechanical allodynia. Group (2) rats in which insulin treatment from 7-days post-STZ administration restored euglycaemia and reversed polydipsia and hyperphagia, were protected against the development of mechanical allodynia and reduced weight gain for the 5-wk study duration, while rats from Group (3) with incomplete glycaemic control developed levels of polydipsia, hyperphagia, reduced weight gain and mechanical allodynia intermediate between rats in Groups (1) and (2). These findings collectively suggest a direct correlation between the level of glycaemic control and the extent to which mechanical allodynia, a defining symptom of PDN, develops. In Chapter Three, the findings from the preliminary 5-wk study in Chapter Two were used to design a 24-wk longitudinal study of the temporal development of mechanical allodynia and opioid hyposensitivity in STZ-diabetic Wistar rats for comparison with the findings of a similar study previously undertaken by our laboratory using STZ-diabetic Dark Agouti rats (Nielsen et al, 2007). Additionally, this study examined the effects of tight glycaemic control achieved through the use of insulin implants as a means of potentially preventing the development of mechanical allodynia and opioid hyposensitivity for up to 24 weeks in STZ-diabetic Wistar rats. Briefly, STZ-diabetic rats were divided into 3 groups: (1) non-insulin treated STZ-diabetic Dark Agouti rats to provide comparison data with our laboratory’s previously published data in this rat strain (Nielsen et al, 2007), (2) non-insulin treated STZ-diabetic Wistar rats to examine possible between-species differences, and (3) STZ-diabetic Wistar rats which were treated with adjustable-dose s.c. Linplants from Day 7 post-STZ administration to maintain euglycaemia for the remainder of the 24-wk study period. In this 24-wk longitudinal study in STZ-diabetic rats, body weight, 24-hr water intake, paw withdrawal thresholds (PWTs) and BGLs were monitored at fortnightly intervals in all animals in order to document possible temporal changes in the development of diabetic signs and mechanical allodynia in the hindpaws respectively. STZ-diabetic rats underwent 6-wkly opioid antinociceptive testing, using single bolus doses of each of morphine and oxycodone with a 2-3 day washout period between individual opioids in order to assess the potential influence of both diabetes and glycaemic control on opioid potency in these animals. The findings demonstrate that non-insulin treated STZ-diabetic rats of both strains exhibited a decreased rate of body weight gain and polydipsia, as well as progressive development of mechanical allodynia in the hindpaws and loss of morphine potency. Importantly, STZ-diabetic Wistar rats which were treated with insulin to maintain euglycaemia from Day 7 post-STZ administration failed to develop these diabetic symptoms for the duration of the 24-wk study period, highlighting the importance of chronic hyperglycaemia in the development of mechanical allodynia and morphine hyposensitivity in the STZ-diabetic rodent model of PDN. The research described in Chapter Four involved a 22-wk longitudinal study of the development of diabetes and its longterm sensory nerve complications, viz mechanical allodynia and opioid hyposensitivity, in the ZDF rodent model of Type 2 diabetes commencing at 7-wks of age. This study also examined the influence of four different diets fed to separate groups of ZDF rats from 7-wks age, on the time course for the development of diabetes, mechanical allodynia in the hindpaws and opioid hyposensitivity in these animals. Briefly, ZDF rats were sub-divided into four dietary groups, each of which was fed one of the four following diets for 22-wks commencing at 7-wks of age, viz: (a) Purina 5008™, (b) a domestically-produced rat chow of similar composition to Purina 5008 (termed Purina Composition diet), (c) a Diabetogenic diet, or (d) Standard Rat Chow. All rats underwent once-fortnightly measurement of BGLs, body weight, 24-hr water intake, and measurement of PWTs in the hindpaws. Additionally, ZDF rats underwent opioid antinociceptive testing, similar to that previously described for STZ-diabetic rats (Chapter Three), to investigate the influence of diabetes and dietary composition on the antinociceptive potency of single bolus doses of morphine and oxycodone administered at 6-weekly intervals over a 22-wk study period. The afore-mentioned data were compared with the respective data obtained from the pre-diabetic control group of ZDF rats that were euthanised at 7-wks of age prior to the development of hyperglycaemia. The results demonstrate that the ZDF rat develops mechanical allodynia in the hindpaws and opioid hyposensitivity in a temporal fashion, in a manner similar to that previously documented for the STZ-diabetic Wistar rat model of Type 1 diabetes (Chapter Three). For the four diets assessed, there did not appear to be significant differences between dietary groups with respect to the time course and extent of development of hyperglycaemia, mechanical allodynia or opioid hyposensitivity in the ZDF rat model of PDN. The study described in Chapter Five investigated the effect of both diabetes and dietary composition on opioid receptor mRNA expression in tissue samples collected from the five groups of ZDF rats used in the behavioural studies described in Chapter Four and outlined above. Briefly, mRNA expression for each of the - (MOP), - (DOP), and - (KOP) receptors were quantified in mid-brain and spinal cord tissues prepared from 29-wk old diabetic ZDF rats maintained on one of four diets from 7-wks age, and compared with the respective expression levels in samples prepared from pre-diabetic ZDF rats euthanised at 7-wks of age. Overall, the findings suggest that diabetes does not alter opioid receptor mRNA expression in the mid-brain or spinal cord of diabetic ZDF rats at 29-wks of age relative to the corresponding levels of mRNA expression in the mid-brain and spinal cord of pre-diabetic ZDF rats at 7-wks of age. Hence, the marked reduction in the anti-allodynic potency of morphine and oxycodone observed in diabetic ZDF rats at 29-wks of age relative to that observed in pre-diabetic ZDF rats at 7-wks of age (Chapter Four) does not appear to be associated with a decrease in opioid receptor mRNA expression. In Chapter Six, the effect of both advanced diabetes and dietary composition on opioid-agonist stimulated [35S]GTPγS binding was examined in spinal cord tissue membranes from the ZDF rat. Specifically, [35S]GTPγS binding assays were used to assess the ability of a -opioid ligand (DAMGO) to stimulate -opioid receptor coupling to inhibitory G proteins in homogenates prepared from spinal cord samples of 29-wk old ZDF rats maintained on one of four different diets from 7-wks age (Chapter Four), relative to [35S]GTPγS binding in homogenates prepared from spinal cord samples of pre-diabetic 7-wk old ZDF rats. As specific MOP agonist-stimulated [35S]GTPγS binding was significantly decreased in spinal cord homogenates from diabetic ZDF rats at 29-wks of age relative to that for pre-diabetic ZDF rats (7-wks), this may contribute, at least in part, to the morphine hyposensitivity observed in diabetic ZDF rats at 29-wks of age relative to the pre-diabetic ZDF group. However, closer examination of these data revealed that specific MOP agonist-stimulated [35S]GTPγS binding above basal did not differ significantly between the pre-diabetic group and the longterm diabetic group of ZDF rats. Instead, there was significantly lower basal [35S]GTPγS binding in the spinal cord of ZDF rats at 29-wks c.f. 7-wks of age. Together, the findings suggest that impaired basal G-protein function rather than impaired coupling of MOP-r to its inhibitory G-protein may, at least in part, underpin -opioid agonist hyposensitivity in 29-wk ZDF rats. Finally, Chapter 7 contains a brief description of the main conclusions and discussion of the relevance of this doctoral research project, including potential future research directions.
|
Page generated in 0.0476 seconds